> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# PhRMA Strategies to Enhance Trial Diversity
- URL: https://www.fdaweb.com/phrma-strategies-to-enhance-trial-diversity/
- Published: 2021-11-16T12:00:00.000Z
- Updated: 2026-09-14T17:22:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150591

Pharmaceutical Research and Manufacturers of America (PhRMA) and the Deloitte Center for Health Solutions have issued a report with five strategies for enhancing diversity in clinical trials during the research and development of new medicines. The [report](https://www.phrma.org/resource-center/Topics/Equity/Five-Key-Strategies-for-Enhancing-Diversity-in-Clinical-Trials?ref=fdaweb.com), “Enhancing Clinical Trial Diversity: Stakeholder Perspectives on Advancing Research Through Representative Clinical Trials,” is based on a year-long stakeholder engagement effort that included research and feedback from more than 500 stakeholders across over 150 organizations including community stakeholders, experts on clinical trials and in racial justice, patient advocates, healthcare practitioners, drug companies, academia, and more.

The strategies are: 

- create a network of clinical trial sites in underserved communities;
- develop a diverse pool of investigators and staff;
- establish long-term relationships and invest in the community;
- engage the community in conversations; and
- provide sustainable support and standardized platforms.